A study on the reactogenicity, safety, immune response, and efficacy of a targeted immunotherapy against HSV in healthy participants aged 18-40 years or in participants aged 18-60 years with recurrent genital herpes

Trial Identifier: 215336
Sponsor: GlaxoSmithKline
Start Date: March 2022
Primary Completion Date: June 2025
Study Completion Date: June 2025

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
AUSTRALIA, NSW Darlinghurst, NSW, AUSTRALIA, 2010
AUSTRALIA, NSW Sydney, NSW, AUSTRALIA, 2010
BELGIUM Antwerpen, BELGIUM, 2000
BELGIUM Brussels, BELGIUM, 1000
BELGIUM Edegem, BELGIUM, 2650
BELGIUM Gent, BELGIUM, 9000
CANADA, QC Montreal, QC, CANADA, H2L 4E9
ESTONIA Tartu, ESTONIA, 50106
GERMANY Berlin, GERMANY, 10117
GERMANY Berlin, GERMANY, 10439
GERMANY Bochum, GERMANY, 44787
GERMANY Frankfurt, GERMANY, 60596
GERMANY Hamburg, GERMANY, 20146
GERMANY Koeln, GERMANY, 50674
SPAIN Barcelona, SPAIN, 08001
SPAIN Barcelona, SPAIN, 08015
SPAIN Madrid, SPAIN, 28010
SPAIN Madrid, SPAIN, 28040
SPAIN Madrid, SPAIN, 28222
SPAIN Marbella, SPAIN, 29600
UNITED_KINGDOM Brighton, UNITED_KINGDOM, BN2 1ES
UNITED_KINGDOM Liverpool, UNITED_KINGDOM, L7 8XP
UNITED_KINGDOM London, UNITED_KINGDOM, WC1E 6JB
UNITED_KINGDOM Southampton, UNITED_KINGDOM, SO14 0YG
UNITED_STATES, AZ Phoenix, AZ, UNITED_STATES, 85015
UNITED_STATES, KS Wichita, KS, UNITED_STATES, 67207
UNITED_STATES, MO Kansas City, MO, UNITED_STATES, 64114
UNITED_STATES, NY Rochester, NY, UNITED_STATES, 14609
UNITED_STATES, VA Richmond, VA, UNITED_STATES, 23219
UNITED_STATES, WA Seattle, WA, UNITED_STATES, 98105